Abstract-After 2 recent genetic studies in mice addressing the developmental origins 1 and regenerative activity of cardiac cKit + cells, 2 2 additional reports by Sultana et al 3 and Liu et al 4 provide further information on the expression of cKit in the embryonic and adult hearts. Here, we synthesize the findings from the 4 distinct cKit models to gain insights into the biology of this important cell type.
I
n 1998, Anversa et al 5, 6 provided the first evidence that the mammalian heart is not a terminally differentiated organ, demonstrating the production of new cardiomyocytes in adulthood. Although intense debate still exists on the exact rate at which this occurs, [7] [8] [9] [10] [11] this paradigm changing observation has been subsequently documented with sophisticated animal models 8, 12, 13 and with 14 C-dating experiments in humans. 8, 9 After this initial experiment, evidence emerged that extracardiac cells, some of which express cKit, could contribute to cardiac cell renewal. [13] [14] [15] [16] [17] In 2003, cKit + cells in the heart were identified as resident cardiac stem cells, capable of generating new coronary vessels and cardiomyocytes in response to injury. 18 These cells were described to reside in cardiac stem cell niches 19 ; were capable of ex vivo propagation and clonal expansion; exhibited capacity for in vitro and in vivo differentiation into cardiomyocytes, endothelial cells, and smooth muscle cells 20, 21 ; participated in the in vitro formation of cardiospheres similar to neural stem cells [22] [23] [24] ; and were negative for hematopoietic lineage markers. 18, 19 Several groups demonstrated ex vivo propagation of cardiac stem cells that were subsequently transplanted in injured hearts leading to enhanced regeneration via mechanisms involving their direct differentiation into new cardiomyocytes and vessels. 18, 21, 23 These observations warranted the approval of clinical trials from the Food and Drug Administration to test the safety and efficacy of resident cardiac stem/progenitor cells for the treatment of human heart disease (NCT00474461; NCT00893360). 25, 26 In 2014, a study by van Berlo et al 2 reported that cKit cells in the heart have minimal cardiomyogenic ability; hence, their therapeutic importance may be marginal. Two mouse lines, carrying 2 different versions of Cre recombinase (a recombinase enzyme derived from the P1 bacteriophage; either a tamoxifen-inducible MerCreMer [a version of Cre, fused to 2 copies of a mutant murine estrogen receptor ligand-binding domain {amino acids 281-599} with a G525R substitution] or a noninducible Cre-IRES-eGFPnls [nls stands for nuclear localization signal]) under the control of the endogenous cKit promoter and Cre-reporter genes, were engineered to track the fate of cKit-expressing cells in the heart (Figure) . Expression of reporters was analyzed either before or in response to myocardial infarction injury. In both cases, van Berlo et al 2 found that the vast majority of the cardiac cells that had undergone Cre-mediated recombination were endothelial cells and only rarely cardiomyocytes. This finding led the authors to conclude that cKit + cardiac cells "may be dedicated vascular endothelial progenitor cells…[not] capable of regenerating the heart with new contracting myocardium to a physiologically meaningful extent." 11 However, because cKit expression occurs in several cardiac and extracardiac cell lineages, 27 the role and identity of cardiac cKit + cells remained elusive. Do the endothelial cells and cardiomyocytes arise from the same cKit-expressing lineage or are there multiple cKit + lineages in the heart? 27 Why do cKit + cells differentiate into far fewer cardiomyocytes than endothelium? Are they bona fide cardiovascular progenitors or do they represent noncardiomyogenic cells that stochastically (trans)differentiate into myocardium?
Our group performed a high-resolution genetic lineagetracing study using a different mouse line that expresses the CreER T2 version (a version of Cre, fused to a mutant human estrogen receptor ligand-binding domain [G400V/M543A/ L544A triple mutation]) of Cre recombinase from the endogenous cKit locus and a loxP-STOP-loxP-flanked Cre-reporter allele (Figure) . In addition to addressing some of the issues raised by van Berlo et al, 2 we sought to not only genetically track the fate of cKit + cells but also to identify their lineage and role in the heart. 1 Importantly, we showed that cKit marks rare, bona fide cardiomyogenic progenitors in the neural crest lineage (as shown by intersectional genetic fate mapping with a Wnt1-reported mouse) with unequivocal capacity to produce new cardiomyocytes but not coronary endothelial cells. Furthermore, cardiomyocyte differentiation is governed by spatiotemporal changes in the activity of bone morphogenetic protein, a signaling pathway that subsides during migration of cKit + neural crest cells to the heart, 28 reducing an important activator of cardiomyocyte differentiation. Thus, the limited contribution of cKit + cells in cardiomyocytes is not a function of deficient cardiomyogenic capacity but rather reflects a nonpermissive milieu. 
Overview of the cKit Knockin Alleles
To monitor real-time expression of cKit, the authors developed 2 new reporter mouse lines (Figure) . In the first mouse line, transcription of cKit results in nuclear expression of the red fluorescent protein tdTomato (tandem dimer tomato red fluorescent protein; c-Kit
H2B-Tomato/+
). The second is a dual reporter mouse line, where transcription of cKit results in nuclear expression of β-galactosidase, which may be irreversibly substituted by nuclear expression of green fluorescent protein on Cre-mediated recombination (c-Kit
nLacZ-H2B-GFP/+
). Importantly, once a cell no longer expresses cKit (ie, differentiates into a cKit-negative derivative), expression of the reporter genes (either TdTomato, GFP, or nLacZ [nuclear β-galactosidase]) should no longer be detectable.
Both cKit reporter mouse lines exhibited broad reporter gene expression in the heart, during both development and adulthood. 3 The degree of cKit reporter gene expression exceeds essentially all reports of cKit expression or fate-mapping studies in rodents, 1,2,13,18,21,29-34 large mammals, 18, 35, 36 and humans. 20 For example, although van Berlo et al 2 showed that reporter gene expression under their Kit-Cre-IRES-eGFPnls allele "…was always coincident" with endogenous cKit protein expression in vivo, they report that eGFPnls is not broadly expressed in the heart but marks a rare mononuclear cell population. Similarly, databases, such as the Human Protein Atlas Insight into this discrepancy is derived from RNA in situ hybridization data, which overlapped with in situ cKit transcriptional activity and reporter gene expression, suggesting that the 2 new alleles mark cells with levels of cKit transcriptional activity that do not result in protein expression sufficient for conventional immunodetection. clarified a later appearance of these cells in development, supporting the idea that they are likely of cardiac neural crest and not mesodermal origin. This was further substantiated with an intersectional fate mapping approach in which the cKit CreERT2/+ mouse was crossed to mice carrying a Wnt1::Flpe and dual recombinase-responsive indicator alleles. Moreover, the majority of these cells were found within the interventricular septal wall 1 and not the endocardium as was thought. 40 After these findings, the question that remained unanswered was whether a relationship existed between the cKit + / Nkx2. 
Identity of cKit + Cell Lineage(s) in the Heart

cKit + Cardiac Cells and Cardiomyocyte Regeneration
A consistent finding between the 4 independent genetic lineage fate-mapping studies of cKit in the heart is that the degree to which cKit + cells generate new cardiomyocytes in vivo during embryogenesis, aging, and myocardial injury is lower than expected, based on previous reports. 13, 18, 21 However, there are important differences in the analysis and interpretation of the genetic findings.
Both genetic fate-mapping studies by van Berlo et al 2 and Sultana et al 3 interpret the minimal degree of cardiomyogenesis from cKit + cells as a justification for discounting cKit + cardiac progenitors as a physiologically relevant precursor for cardiac formation, therefore questioning efforts to use cultureexpanded cKit + cells as a therapeutic strategy for myocardial regeneration. However, a recombinase-based genetic fatemapping study provides a binary method for tracking the activity of a given cell via the activity of a single gene and does not measure whether a cell holds an inferior or superior ability to differentiate. Thus, the assumption that the limited detection of cKit reporter genes in cardiomyocytes translates into limited cardiomyocyte differentiation capacity of cKit + progenitors is not being tested under these 2 experimental studies and should not, therefore, inform conclusions on cardiomyogenic ability and therapeutic importance of cKit + cells. Another key example where a genetic fate map does not reflect therapeutic importance comes from studies in cardiomyocyte proliferation. Genetic lineage-tracing studies of proliferating cardiomyocytes illustrate that, similar to cKit + cardiac progenitors, the degree of myocardial regeneration from pre-existing cardiomyocytes is functionally insignificant (Table) . 12, 13, 43, 44 Intriguingly, here, the findings are not interpreted as therapeutically irrelevant, but as a justification for targeting cardiomyocyte replication as a meaningful therapeutic strategy for myocardial regeneration. 11, 12 We would use the same logic to continue to support the use of cKit + cells in therapeutic trials.
The differentiation capacity of cKit + cardiac progenitors is tested in the study by Hatzistergos CreERT2/+ alleles were not cardiomyocytes. However, because the Cai cKit reporter alleles seem to exhibit high sensitivity and label cells even with low cKit transcriptional activity, the possibility that some of the cardiomyocytes detected by Sultana et al 3 are pre-existing cardiomyocytes expressing low levels of cKit, 46 or perhaps cKit-derived cTnT + cells at early stages of cardiogenic specification with residual cKit (or cTnT) expression, cannot be excluded.
Discussion
The identification of bona fide cardiac progenitors in the postnatal heart is a major milestone in the field of cardiovascular research that would signify the departure from the longstanding view of human heart disease as incurable. In our view, this milestone has now been reached through the development of 7 elegant research reagents, designed to address the cKit controversy.
Despite the heated debates and provocative headlines that are expected to characterize any type of research with such profound implications for human disease, all 4 independently conducted genetic lineage fate-mapping studies of cKit with 7 different knockin alleles unambiguously recorded the presence of cKit + cardiomyogenic progenitors in the embryonic and postnatal mouse hearts. The physiological role of these cells in cardiomyogenesis may not be as extensive as was previously thought, but the fact that this unequivocal and evolutionarily conserved event is interpreted to mean that these cells are not cardiac progenitors is at odds with the current experimental data. [1] [2] [3] [4] The intriguing similarities and differences on cardiac cKit expression that have been presented by these mouse lines ( Figure) underline the vastness under which the cardiomyogenic and vasculogenic programs are operated in mammals. The development of these new reagents offers a unique opportunity to comprehensively study the role of cKit in the heart and identify possible pathways for deploying cKit + cells for therapeutic myocardial regeneration. For example, although pharmacological or genetic modulation of the cardiac bone morphogenetic protein pathway may be required for therapeutically enhancing the cardiomyogenic activity of the cKit + / Nkx2.5 + progenitor lineage, 1 whether bone morphogenetic protein pathway plays a role in vasculogenic cKit + cells is unknown and needs to be explored because they are likely the most abundant cKit + population in the heart. Similarly, we have previously shown that endogenous cKit + /Nkx2.5 + progenitors may be therapeutically stimulated with mesenchymal stem cell-based therapy. 35, 47, 48 However, whether mesenchymal stem cells affect the cKit + vasculogenic lineage is unknown. The combined use of >1 cKit knockin alleles may help address these questions and others.
On the other hand, these expression differences are also indicative of the inherent limitations of the Cre-loxP knockin approach. The results from these studies may have been skewed by many possible factors, such as abnormal behavior of cKit + cells because of inactivation of the targeted allele, limited detection sensitivity of cells with physiologically low cKit expression again because of allelic inactivation, improper expression of Cre from the cell of interest, improper expression of the reporter genes from the cell of interest, etc, all of which have been extensively discussed elsewhere. 49 Thus, caution should always be exercised when interpreting the knockin genetic fate-mapping findings.
In summary, all independently conducted Cre-loxP knockin genetic fate-mapping studies of cKit identify a rare, cKit + bona fide cardiomyogenic cell lineage in the heart. These cells are likely of cardiac neural crest origin and are distinct from the mesodermal cKit + vasculogenic lineage, which is abundantly present in the heart. More work is required to understand why these cells with clear-cut ability to generate cardiac myocytes enter the heart at a time when a required signal for their differentiation has waned.
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